Appendix 3. Direct Mail Letter

Date

Dear Healthcare Professional:

Eli Lilly and Company (Lilly) wishes to remind you of important information for FORTEO® (teriparatide [rDNA origin] injection) related to the following topics:

- potential risk of osteosarcoma
- proper patient selection and 2-year maximum lifetime duration of treatment
- the voluntary FORTEO Patient Registry

Please take time to read the attached document entitled:

Highlighted Information for Prescribers,
Potential Risk of Osteosarcoma and the Voluntary FORTEO Patient Registry

Please refer to the Full Prescribing Information for further product information.

We invite you to contact our Medical Information Department at 1-866-4FORTEO (1-866 436-7836) or visit www.FORTEO.com if you have any questions about the information contained in this letter or in the attached overview.

Sincerely,

Appropriate Lilly signee and department
Eli Lilly and Company

Enclosure: Highlighted Information for Prescribers; Full Prescribing Information